Latest Onyx Pharmaceuticals Inc. Stories
Study Met Primary Endpoint of Progression-Free Survival THOUSAND OAKS, Calif.
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Feb.
US Submission Designed to Support Conversion From Accelerated to Full FDA Approval and Expansion of Current Approved Indication THOUSAND OAKS, Calif.
2014 GAAP EPS Were $6.70 THOUSAND OAKS, Calif., Jan. 27, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2014.
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition THOUSAND OAKS, Calif.
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
-Dr. Cagnoni Joins Non-Profit Organization Focused on Fostering Innovation and Collaboration to Strengthen the Bay Area BioEconomy- SAN FRANCISCO, Sept.
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug.
Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug.